366 results about "Zika virus" patented technology

Herein disclosed are rapid real-time isothermal multiplex methods of detecting, identifying and quantifying bacterial, viral, and protozoan nucleic acids in a sample. These include contacting the sample with two or more sets of pathogen-specific reverse transcription loop-mediated isothermal amplification primers and novel oligofluorophores specific for the target bacterial, viral, and parasitic nucleic acids of interest such as human immunodeficiency virus, Ebola virus, Marburg virus, Yellow fever virus, hepatitis-B virus, Lassa fever virus, Plasmodium, hepatitis-C virus, hepatitis-E virus, dengue virus, Chikungunya virus, Japanese Encephalitis virus, Middle Eastern Respiratory Syndrome Corona virus, Mycobacterium, West Nile virus, Cytomegalovirus, Parvovirus, Leishmania, Trypanosoma, and Zika virus nucleic acids, under conditions sufficient to produce detectable real-time amplification signals in about 10 to 40 minutes. The amplification signals are produced by pathogen-specific fluorogenic labels included in one or more of the primers. Also, novel reaction and sample lysis buffers, primers, and kits for rapid multiplex detection, quantification, and identification of bacterial, viral, and protozoan nucleic acids by real-time isothermal amplification are herein disclosed.

The invention discloses a human monocolonal antibody with high neutralization activity for Zika virus and application thereof, and belongs to the technical field of medicines. Escherichia coli-expressed Zika E protein is taken as an antigen, a memory B cell capable of specifically binding the Zika E protein is screened from PBMCs of a Zika patient in convalescence through flow sorting, then the screened single B cell is subjected to RT-PCR to obtain a variable region sequence and fragment of the antibody, and the variable region sequence and fragment of the antibody are further connected to anexpression vector together with a constant region. After the expression and purification of mammalian cells, a serious of function tests including binding force with ZIKE-E protein, in-vitro neutralization effect, in-vivo protective capability and the like are carried out, and 3 strains of the human monocolonal antibody with full protection against Zika virus infection are obtained.